Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
Primary Aim Determine the response rate and time to progression of the combination of
thalidomide, interferon, and octreotide in patients with unresectable hepatocellular
carcinoma (cancer of the liver that can't be treated surgically).
Secondary Aims
1. Determine the toxicity of this combination in this population.
2. Determine the survival of this patient cohort treated with the combination.
3. Determine the percent of patients with hepatocellular carcinoma who have a positive
octreotide scan.